Company Profile for Aurinia Pharmaceuticals Inc.
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently in the recruitment and enrollment phase of its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
|
Company: |
Aurinia Pharmaceuticals Inc. | |
|
|
||
|
Headquarters Address: |
#1203 - 4464 Markham Street | |
| Victoria, BC V8Z 7X8 | ||
| Canada | ||
|
Main Telephone: |
250-708-4272 | |
|
Website: |
||
|
Ticker/ISIN: |
AUPH(NASDAQ)/CA05156V1022 | |
| AUP(TSX)/CA05156V1022 | ||
|
Type of Organization: |
Public | |
|
Industry: |
Pharmaceutical | |
|
Key Executives: |
CEO: Stephen Zaruby |
|
|
COO: Michael Martin |
||
|
CFO: Dennis Bourgeault |
||
|
Investor Relations |
||
|
Contact: |
Michael Martin | |
|
Phone: |
250-708-4272 | |
|
Email: |
||
Source: Aurinia Pharmaceuticals Inc.
Released February 6, 2015
